Statins for Attenuating Cardiotoxicity in Patients Receiving Anthracyclines: A Systematic Review and Meta-Analysis

Anoop Titus, Huzaifa Ahmad Cheema, Arman Shafiee, Niloofar Seighali, Abia Shahid, Karan B. Bhanushali, Ashish Kumar, Safi U. Khan, Sumanth Khadke, Paaladinesh Thavendiranathan, W. Gregory Hundley, Marielle Scherrer-Crosbie, Anju Nohria, Tomas G. Neilan, Sourbha S. Dani, Khurram Nasir, Sarju Ganatra

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Anthracycline chemotherapy causes cardiotoxicity, and the evidence regarding the benefit of concomitant statin use in reducing it remains uncertain. We conducted a meta-analysis of studies using statins and anthracyclines by searching PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from inception until April 10, 2023. Our analysis included 3 observational studies and 4 RCTs, including the STOP-CA trial released in ACC23. Statin prescription significantly reduced cardiotoxicity in cancer patients receiving anthracycline chemotherapy (OR 0.46, 95% CI: 0.33-0.63; I2: 0%). However, no significant difference was observed in the decline of left ventricular ejection fraction (LVEF) from baseline (MD 4.15, 95% CI: -0.69 to 8.99, I2: 97%). These findings demonstrate the protective effect of concomitant statin prescription.

Original languageEnglish (US)
Article number101885
Pages (from-to)101885
JournalCurrent Problems in Cardiology
Volume48
Issue number10
Early online dateJun 17 2023
DOIs
StatePublished - Oct 2023

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Statins for Attenuating Cardiotoxicity in Patients Receiving Anthracyclines: A Systematic Review and Meta-Analysis'. Together they form a unique fingerprint.

Cite this